Alzamend Neuro (ALZN) investor relations material

Company overview and business model

• Focuses on developing and commercializing patented therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD through two lead candidates: AL001 and ALZN002.

• AL001 is an ionic cocrystal of lithium, showing superior brain penetration and tolerability in clinical trials compared to standard lithium carbonate.

• ALZN002 is an immunotherapy vaccine using autologous dendritic cells to target amyloid-beta proteins in Alzheimer's, aiming for a safer, longer-lasting effect than monoclonal antibodies.

• Pipeline advancement includes partnerships with Massachusetts General Hospital and Harvard Medical School for Phase II trials and ongoing efforts to expand indications and delivery methods.

Financial performance and metrics

• The company has experienced recurring losses and negative cash flows, with an audit opinion expressing substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of common stock by the selling stockholder; proceeds from the sale of preferred shares are intended for working capital and general corporate purposes.

• Committed equity financing agreement allows for up to $25 million in preferred share sales, subject to closing conditions and staged payments.